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Gene silencingThe discovery of siRNA has been an important step in gene therapy, but the problem of delivering siRNA to a
target organ limits its use as a therapeutic drug. Liposomes can be used as a nonviral vector to deliver siRNA
to target cells. In this study we developed a novel method of producing asymmetric liposome particles (ALPs)
with highly efﬁcient siRNA encapsulation. Two kinds of lipid inverted micelles were prepared for the purpose
of obtaining ALPs. The inner one is composed of ionizable cationic 1,2-dioleoyl-3-dimethylammonium-pro-
pane (DODAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), which entrap siRNA, and the
outer one is composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), DOPE, polyethylene glycol-
1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine (PEG-PE), and cholesterol. After mixing the inverted
micelles, ALPs encapsulating siRNA were obtained by solvent evaporation and dialysis. This process allowed
more than 90% siRNA encapsulation as well as the negatively charged surface. The ALPs protected siRNA from
ribonuclease A degradation. ALPs without any surface modiﬁcation elicited almost no uptake into cells, while
the surface-modiﬁed ALPs with a polyarginine peptide (R12) induced nonspeciﬁc cell penetration. The con-
jugation of the anti-human epidermal growth factor receptor antibody (anti-EGFR) to ALPs induces an EGFR-
mediated uptake into the non-small cell lung cancer cell lines but not into NIH-3T3 cells without the receptor.
The siRNA encapsulated in ALPs showed the R12- or anti-EGFR-dependent target gene silencing in NCI-H322
cells. These properties of ALPs are useful for target-speciﬁc delivery of siRNA after modiﬁcation of ALPs with a
target-speciﬁc ligand.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The discovery of RNA interference (RNAi) opened a new window
for the treatment of gene-related diseases such as cancer [1–5].
Small interfering RNAs (siRNAs) induce sequence-speciﬁc cleavage
of their target mRNA through the endogenous RNA-induced silencing
complex [6,7]. Therefore, siRNAs have great potential in the treat-
ment of diseases caused by genetic disorders [8]. However, negatively
charged siRNAs cannot penetrate the cell membrane, and siRNAs are
rapidly eliminated by nucleases in the blood and body ﬂuids [9,10].
Appropriate delivery systems involving the use of vectors such as
siRNA carriers have been developed to enhance the target delivery
of siRNA to speciﬁc cells and to improve the cellular uptake by
means of systemic administration.
Viral systems such as retroviruses, adenoviruses, adeno-associated
viruses are powerful tools for efﬁcient gene delivery, but they haveCenter, KRIBB, 125 Gwahak-ro,
82 42 860 4169; fax: +82 42
rights reserved.major disadvantages such as inﬂammation and oncogenic potential
[9,11]. Moreover, they cannot be used for the delivery of synthetic
siRNAs. Because of these disadvantages, the research has focused on
non-viral vectors for siRNA delivery.
Many cationic polymers can spontaneously produce particles
called polyplexes by polymer mixing with nucleic acid. Positively
charged polyplexes electrically interact with the negatively charged
siRNAs, and they carry the siRNA, effectively protect it from enzyme
degradation, and promote the uptake of siRNA into cells [12,13]. The
disadvantages of cationic polyplexes are removal by means of the re-
ticuloendothelial system (RES) and accumulation at the primary or-
gans as a result of nonspeciﬁc interactions with blood components
[14–17].
Lipoplexes, which are siRNA-cationic lipid complexes, were devel-
oped to deliver siRNAs into cells [18,19]. The lipoplex encapsulation
depends on the charge interaction between siRNA and cationic lipids.
Although lipoplexes efﬁciently encapsulate and protect siRNA from
nuclease degradation, the rapid removal and clearance of lipoplexes
from blood by RES clearance and the accumulation in the primary
organ during systemic delivery are major problems for their usage as
a carrier [17,18,20]. This problem is overcome by using polyethylene
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rect contact with the blood components. The PEGylation decreases
the RES clearance of the lipoplex [21], and the PEGylated liposomes
also have some advantages, such as accumulation at the tumor site
[22] and prolonged circulation of the liposome in mice [23]. In addi-
tion, the encapsulation of siRNA inside the liposome is considered
the best way of protecting siRNA from nuclease degradation. Several
methods have reportedly achieved good encapsulation of siRNA in
PEGylated liposomes [10,24,25]. These formulations are insufﬁcient
to protect the nonspeciﬁc delivery that is needed for target-speciﬁc
delivery of siRNA. Recently, a spontaneous vesicle formation method
was used to successfully encapsulate siRNA [10,26], and clinical trials
are currently in progress. However, the main in vivo delivery mecha-
nism is dependent on the enhanced permeability and retention effect.
In contrast, neutral or negatively charged liposomes can minimize the
nonspeciﬁc absorption of siRNA into cells but their lower efﬁciency in
terms of encapsulating siRNA is a major disadvantage [27].
In this paper, we describe a novelmethod of producing asymmetric
liposome particles (ALPs) which have a high efﬁciency in encapsulat-
ing siRNA and a negatively charged surface. The cationic lipids that en-
capsulate siRNA are localized at the inner layer, whereas the neutral
and PEGylated lipids face the outer environment. The ALPs were un-
able to internalize into cells, but their surface modiﬁcation by a poly-
arginine peptide or a target-speciﬁc antibody (anti-EGFR) induced
the cellular uptake of ALPs and siRNA-dependent gene-silencing ef-
fects. We believe that ALPs may be useful for target-speciﬁc systemic
delivery of siRNA after conjugationwith proper target-speciﬁc ligands.
2. Materials and methods
2.1. Material
The lipids for this study, which were purchased from Avanti Polar
Lipids, Inc. (USA), were 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyl-
ene glycol)-2000] (mPEG-PE), 1,2-distearoyl-sn-glycero-3-phospho-
ethanolamine-N-[maleimide(polyethylene glycol)-2000] (miPEG-PE),
1,2-dioleoyl-3-dimethylammonium-propane (DODAP), 1,2-dioleoyl-
3-trimethylammonium-propane (DOTAP), and cholesterol (CH).Fig. 1. Schematic of the ALP preparation. The inner and outer lipid ﬁlms were hydrated with
outer inverted micelles were prepared by sonication after the addition of diethylether. The i
ibrated with HBS.TRIzol reagent and lipofectamine 2000 were obtained from Invi-
trogen (USA), and an RT-PCR kit was obtained from New
England Biolabs (USA). A solid-phase method involving Fmoc
chemistry (REF) was used to synthesize the cell-penetrating pep-
tide R12 (RRRRRRRRRRRRGGC). All other chemicals were pur-
chased as analytical and molecular biology grades. Double-strand
siRNAs were purchased from Samchully Pharm Co., Ltd (Korea),
and ﬂuorescein isothiocyanate (FITC)-labeled siRNA (FITC-siRNA)
was obtained from the Bioneer Corporation (Korea). Samples of dial-
ysis membrane with molecular weight cut-off values of 10 K, 50 K, and
300 K were purchased from Spectrum Laboratories (USA). The non-
small cell lung carcinoma (NSCLC) cells A549, NCI-H322, NCI-H460,
and NIH-3T3 were obtained from ATCC (USA). 2-Iminothiolane·HCl
was supplied by Thermo Scientiﬁc (USA). Anti-EGFR (Erbitux) was
obtained from Merck & Co. Inc. (USA), and anti-human IgG antibody-
cy3 and streptavidin-Cy3 were obtained from Sigma-Aldrich (USA),
respectively. All solutions were made up in DEPC water.
2.2. ALP preparation
As shown in Fig. 1, the ALPs were prepared by means of a modiﬁed
reverse phase evaporation method [28]. The inner and outer inverted
micelleswere prepared separately in two different test tubes. The lipid
components of the outer layer were DSPC, DOPE, PEG-PE (which is a
mixture of mPEG-PE and miPEG-PE), and CH with a molar ratio of
3:3:2:4 or 4:3:1:4 (1.7 μmol total). The lipid components of the
inner layer were DODAP and DOPE with a molar ratio of 9:1
(1.5 μmol total). After making the outer and inner thin ﬁlms, we hy-
drated the outer lipid ﬁlm in a mixture of 200 μl HBS (20 mM HEPES
and 150 mM sodium chloride; pH 7.5) and 120 μl ethanol;we then hy-
drated the inner lipid ﬁlm in 150 μl of 150 mM sodium citrate (pH 4)
containing 100 μg of siRNA. To make the outer and inner inverted mi-
celles, we added 600 μl and 400 μl samples of diethyl ether to the outer
and inner layer solutions, respectively, and sonicated themixturewith
a cup-horn probe of a Sonics ultrasonic processor (Sonics & Materials,
USA). The inverted micelles were mixed, and the diethyl ether was
evaporated under nitrogen blowing. The ALPs that encapsulated
siRNA (siRNA/ALPs) were dialyzed with a 10 K membrane in HBS at
4 °C to remove the remaining organic solvents, and the ﬁnal volume
was adjusted to 500 μl by adding HBS. The same method was used tosodium citrate (pH 4.0) containing siRNA and HBS/ethanol, respectively. The inner and
nverted micelles were then mixed and evaporated. The resulting liposomes were equil-
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FITC-siRNA was used instead of the siRNA. To modify the ALP surface,
we added 55 nmol miPEG-PE to the outer layer lipids. We also made
liposomes by changing the inner pH from 4 to 5 and by using DOTAP
instead of DODAP. The particle sizes and zeta potentials of the ALPs
were analyzed with an ELS-Z zeta-potential and particle size analyzer
(Photal Otsuka Electronics, Japan).
2.3. Evaluation of siRNA encapsulation in ALPs
The efﬁciency with which ALPs encapsulate siRNA was monitored
by using a 4% agarose gel electrophoresis method with a Tris-borate-
EDTA (TBE) buffer system. To analyze the encapsulation of siRNA, we
loaded the ALPs on the 4% agarose gel in the TBE buffer with 0.5 μg/ml
ethidium bromide in the absence and presence of 1% nonidet-P40
(NP40). After the electrophoresis, siRNA bands were visualized with
a gel documentation system using an ultraviolet transilluminator
(Bio-Rad, USA). The siRNA band intensities were determined by
means of densitometric analyses using the Bio2D program (Vilber
Lourmat, France).
2.4. Nuclease protection assay of siRNA in ALPs
To evaluate the nuclease protection of the siRNA encapsulated in
ALPs, we mixed 4 μl of 20 μg/ml ribonuclease A (RNase A) or 8 μl of
fresh mouse serum with 8 μl of siRNA/ALPs containing 1.6 μg siRNA.
The mixture was then incubated at 37 °C for up to 24 h. Agarose gel
electrophoresis was conducted in the presence of 1% NP40 to monitor
the remaining siRNA. An equivalent amount of free siRNA was used as
a positive control to check the RNase A activity.
2.5. Serum stability and toxicity of siRNA/ALPs
Serum stability of siRNA/ALPs was studied by turbidity change in
70% fetal bovine serum (FBS). Thirty microliters of siRNA/ALP solution
was mixed with 70 μl of HBS or FBS in the 96 well culture plate, and
then the mixtures were and incubated at various times up to 24 h at
room temperature. One hundred microliters of HBS or a mixture of
70% FBS and 30% HBS, respectively, was used as a control. The turbid-
ity of the mixtures was measured by the absorbance at 550 nm. The
relative absorbance values (%) were calculated according to (As−
Ac)t/(As−Ac)0×100, where As and Ac denote the mixtures of
siRNA/ALP and FBS or HBS and the corresponding control, respective-
ly, and (As−Ac)t and (As−Ac)0 denote the absorbance differences at
given time (t) and initial time (0), respectively.
The cell toxicity of siRNA/ALPs was measured by cell viability. The
siRNA/ALP solution (6.4 mM lipid concentration) was serially diluted
in DMEM containing 10% fetal bovine serum (DMEM-FBS) up to 1:4
(1.2 mM lipid concentration). One hundred microliters of the diluents
was treated to 40% to 50% conﬂuent cells in 96wells, and the cells incu-
bate for 24 h in CO2 incubator. The cell viability was measured accord-
ing to the manufacturer's protocol by using WST-1 kit (Takara, Japan).
2.6. Preparation of a Fab′ fragment
A Fab′ fragment of the anti-EGFR was obtained in a subsequent
treatment of the antibody with pepsin and 2-mercaptoethylamine-
HCl as shown in Supplementary Fig. 1A. Brieﬂy, a 4 mg/ml to 5 mg/ml
sample of the antibody was equilibrated with 0.1 M of sodium acetate;
the pH level was 4.0. The sample was digested with 0.1 mg/ml pepsin
(Sigma, USA). After 2 h to 3 h of incubation, the reaction was stopped
by adding a tenth of the volume of 1.5 M Tris–HCl, pH 8.8. The resulting
F(ab′)2 was dialyzed against PBS–EDTA (PBS solution containing 5 mM
EDTA) and then reduced in a 90 min treatment with a tenth of the
volume of 6 mg/ml 2-mercaptoethylamine–HCl. The resulting Fab′
was dialyzed against PBS–EDTA. All the products were analyzed bymeans of a reducing and non-reducing process of SDS-polyacrylamide
gel electrophoresis (SDS-PAGE).
2.7. Surface modiﬁcation of ALPs
To conjugate R12 to ALPs, we added R12with 5 times molar excess
than miPEG-PE to the ALP solution. The mixture was incubated for 3 h
at room temperature. The unbound peptide was removed by dialysis
with a 50 K membrane in HBS. To conjugate the anti-EGFR and Fab′
to ALPs, they were initially thiolated for 20 min to 30 min with a ten-
fold to twenty-fold molar excess 2-iminothiolane. The thiolated pro-
teins were then dialyzed in PBS–EDTA, and then the thiolations were
estimated by an Ellman assay using 5,5′-dithiobis-(2-nitrobenzoic
acid. Fifty micrograms of thiolated antibody (tAb) or Fab′ (tFab′) and
100 μg of unmodiﬁed Fab′ were incubated for 16 h to 20 h at 16°C
with 100 μl of an miPEG-PE formulation that contained ALPs. The
unreacted maleimide groups of ALPs were neutralized by the addition
of a hundredth volume of 200 mM 2-mercaptoethanol. The resulting
ALPs were mixed with the equal volume of 74% sucrose, and then
were puriﬁed by a buoyant sucrose density gradient centrifugation
with 9%, 25%, 30%, and 37% sucrose concentrations. A 9% fraction con-
taining ALPs was collected and dialyzed against HBS. Agarose gel elec-
trophoresis was used to analyze the encapsulation of siRNA, and SDS-
PAGE was used to analyze the antibody conjugation to the ALPs.
2.8. Immunocytochemistry
The expression of the EGFR on the cell membrane was monitored
by means of immunocytochemistry. The NSCLC cells, namely A549,
NCI-H322, and NCI-H460, and the NIH-3T3 cells were cultured in
micro-slide eight-well microscopy chambers (ibidi, Germany) in
DMEM-FBS. The cells were ﬁxed with 4% formaldehyde in PBS,
washed with PBS, and subsequently incubated for 1 h with the anti-
EGFR and anti-human IgG antibody-cy3. The cells were incubated
for a further 5 min with 2 μg/ml 4,6-diamidino-2-phenylindole
(DAPI) in PBS, and the cell bound antibody was monitored with a
confocal microscope (Carl Zeiss LSM 510 META, Germany).
2.9. Effect of antibody modiﬁcation on the cellular uptake
The EGFR antibody was conjugated with FITC (Sigma, USA) or
biotin-maleimide to test the effect of the modiﬁcation on the
receptor-mediated antibody uptake. For the FITC modiﬁcation, the
antibody was mixed with FITC (with a ﬁvefold molar excess) in
PBS, and the mixture was incubated for 1 h. For the biotin-
maleimide modiﬁcation, tAb was mixed with a tenfold molar excess
sample of biotin-maleimide (Sigma, USA) in PBS–EDTA, and the mix-
ture was incubated for 1 h. All the modiﬁed antibodies were dialyzed
in PBS and applied to the NSCLC cells (A549, NCI-H322, and NCI-
H460) and the NIH-3T3 cells; they were cultured in micro-slide
eight-well microscopy chambers (ibidi, Germany) in DMEM-FBS.
The cells treated with the biotin-modiﬁed antibody were ﬁxed with
4% formaldehyde, permeabilized with 0.1% Triton-X100, and then
treated with streptavidin-cy3. The antibody localizations were mon-
itored with a confocal microscope.
2.10. Cellular uptake assay of ALPs
The NSCLC cells (A549, NCI-H322 and NCI-H460) and the NIH-3T3
cells were cultured in micro-slide eight-well microscopy chambers
(ibidi, Germany) in DMEM-FBS. The cells were then treated with
FITC-siRNA/ALPs modiﬁed by R12, tAb or tFab′ in DMEM-FBS. After
1 day of incubation, the cells were rinsed twice in PBS and ﬁxed
with 4% formaldehyde in PBS at room temperature for 15 min. After
the subsequent DAPI treatment, the cellular uptake of FITC-siRNA
was monitored with a confocal microscope.
Fig. 2. The siRNA encapsulation in ALPs in relation to the inner and outer lipid compo-
sitions and inner pH levels. The encapsulation efﬁciency levels of the ALPs were mon-
itored by using 4% agarose gel electrophoresis with a TBE buffer. The encapsulated
siRNA and the total amount of siRNA were monitored in the absence and presence of
1% NP40, respectively. (A) The inner lipid compositions and pH levels dramatically af-
fect the encapsulation efﬁciency of siRNA. (B) The outer lipid compositions slightly af-
fect the siRNA encapsulation and particle sizes. (C) The negatively stained ALPs with 2%
sodium tungstate (pH 7.0). The outer lipid compositions of (A) were used for DSPC/
DOPE/mPEG-PE/Chol (molar ratio 3:3:2:4), and the inner lipid compositions of (B)
were used for DODAP/DOPE (9:1).
1636 A.A. Mokhtarieh et al. / Biochimica et Biophysica Acta 1818 (2012) 1633–16412.11. Gene-silencing efﬁciency of siRNA/ALPs
To test the gene-silencing efﬁciency of the ALPs that encapsulate
siGL3 (siRNA for GL3-luciferase; antisense: 5′-UCGAAGUACUCAGC-
GUAAGdTdT-3′) [29], we cultured NCI-H322 cells until the con-
ﬂuency level in the DMEM-FBS reached 80% to 90%. The cells were
transfected with a pGL3 control vector (Promega, USA) by means of
lipofectamine 2000 (Invitrogen, USA). They were then cultured for
16 h to 24 h. The transfected cells were subcultured overnight in a
24-well plate and treated for two more days with samples of the
siGL3-Lipofectamine 2000 complex and siGL3/ALPs with or without
modiﬁcation with tAb. The luciferase activity was analyzed with a
Promega luciferase assay system (Promega, USA), and the lumines-
cent lights were monitored with a multilabel plate reader (PerkinEl-
mer VICTOR 3 1420, USA).
To prevent the expression of TMPRSS4 expression, we applied
siTMPR4 (siRNA for TMPRSS4: antisense: 5′-AAGUUGUCGAAACAGG-
CAGAGAACC-3′) to NCI-H322 cells as described previously [30].
Brieﬂy, the siRNA/ALPs (with and without ligand modiﬁcation)
were applied to NCI-H322 cells. Complexes of siTMPR4/25 K poly-
ethyleneimine and siTMPR4/lipofectamine 2000 (LF2K) were used
as controls. After 48 h of post-transfection, we harvested the trans-
fected cells and used an RT-PCR to monitor the TMPRSS4 gene knock-
down. The total RNA was isolated with TRIzol (Invitrogen, Carlsbad,
CA, USA), and cDNA was synthesized with reverse transcriptase. A
PCR ampliﬁcation was performed with TMPRSS4-speciﬁc primers
(5′-CCGATGTGTTCAACTGGAAG-3′ and 5′-CCCATCCAATGATCCAGAGT-
3′ for a 237 bp product; 5′-GATCCACACTGCAGGTGCTG-3′ and 5′-CCA-
CAGACGTGCTGTTTGTC-3′ for a 364 bp product) (Bioneer, Daejeon,
Korea). A fragment of β-actin (5′-GCTCGTCGTCGACAACGGCTC-3′ and
5′-CAAACATGATCTGGGTCATCTTCTC-3′) was also ampliﬁed as an inter-
nal control. The PCR was performed at annealing temperature of 58 °C
for TMPRSS4 and 55 °C for β-actin.
2.12. Cell invasion and cell migration assays
The siTMPR4-transfected NCI-H322 cells (4×104) were plated in a
serum-free medium on 24-well Transwell inserts (Costar, Corning,
NY, USA) coated with 25 μg of Matrigel (BD Biosciences, USA). The
underside of the insert was pre-coated with 2 μg of Collagen I
(Sigma, USA). After 48 h of incubation at 37 °C and 5% CO2, the inserts
were ﬁxed with 3.7% paraformaldehyde/phosphate-buffered saline
and stained with 2% crystal violet. Representative high-power
(×200) ﬁelds were photographed, and the number of cells that had
invaded or migrated was counted in 6 to 8 representative ﬁelds per
Transwell insert. Cell migration assays were performed in a similar
manner but without the Matrigel coating.
3. Results
3.1. Liposome preparation, size and siRNA encapsulation
The reverse-phase evaporation method is suitable for high encap-
sulation of a target molecule [28], but the uniform lipid system make
difﬁculty achieving an encapsulation level of more than 70%. Al-
though the positive charge of cationic liposomes promotes nucleic
acid encapsulation, in vivo target gene delivery to speciﬁc cells is dif-
ﬁcult due to the nonspeciﬁc interaction of positive lipids with the
negatively charged cell surface. To overcome these problems, we de-
veloped ALPs with different components in their outer and inner lipid
layers. Fig. 1 shows the overall scheme for the preparation of ALPs
with highly efﬁcient siRNA encapsulation and a negatively charged
surface. After the evaporation of the organic solvents, the liposome
solution was dialyzed with a 10 K dialysis membrane in HBS. The
nonencapsulated (free) siRNA cannot penetrate the 10 K dialysis
membrane; thus, the nonencapsulated siRNA and the total siRNA inthe ALPs can be estimated by means of agarose gel-electrophoresis
in the absence or presence of 1% NP40, respectively.
To produce ALPs, we initially prepared two different inverted mi-
celles. We used DODAP/DOPE (total: 1.5 μmol; molar ratio: 9:1) with
small head groups for the inner inverted micelle. The inner lipid ﬁlm
was hydrated with a 150 mM citrate buffer (pH 4.0) containing siRNA
to induce the strongly positive charge of DODAP [23]. Under these
conditions, we achieved an encapsulation level of more than 90%
(Fig. 2A). However, changing the inner pH to 5.0 and using DOTAP in-
stead of DODAP prevent almost siRNA encapsulation (Fig. 2A). The
exclusive use of DODAP (100%) prevented the inverted micelle for-
mation and reduced the siRNA encapsulation, whereas a DODAP/
DOPE mixture with a ratio of 1:1 achieved an siRNA encapsulation
level of approximately 90% (data not shown). For the outer inverted
micelle, we used DSPC, DOPE, PEG-PE, and Chol. As shown in
Fig. 2B, we tested various derivatives of phosphatidylcholine and
phosphatidylethanolamine (PE) and found that the DSPC/DOPE com-
bination produces the best results (that is, a higher level of siRNA en-
capsulation and smaller particles). Hydration of the outer lipids in
200 μl HBS (pH 7.5) forms aggregates, but the aggregates can be pre-
vented by adding 120 μl of ethanol. The molar lipid ratio of the outer
versus inner layer was set at approximately 1.06 to 1.07 to provide a
larger surface area for the outer lipid layer. Finally, we ﬁxed the outer
lipid composition as DSPC/DOPE/PEG-PE/Chol (total: 1.6 μmol; molar
ratio: 3:3:2:4 or 4:3:1:4) and the inner lipid composition as DODAP/
DOPE (total: 1.5 μmol; molar ratio: 9:1) with an inner pH level of
4.0. The siRNA encapsulation efﬁciency under optimized conditions
was almost 95%; and the average particle size was about 200 nm
(Fig. 2B and Supplementary Table 1). A TEM image of the ALPs
shows that the particles have a similar size (Fig. 2C). The unencapsu-
lated siRNA could be removed by dialysis using a 300 K dialysis mem-
brane (Fig. 2D). The ALPs have highly negative zeta potentials
(Fig. 2B) and the inside acidic pH (the pH of the liposome solution
Fig. 3. Protection of the siRNA encapsulated in the ALPs from RNase A and mouse
serum. The RNase A (A) and 50% serum (B) were applied to the ALPs that encapsulated
the siRNA and the free siRNA at the indicated time points. The remaining siRNA was
monitored by means of agarose gel electrophoresis in the presence of 1% NP40. NT re-
fers to the non-treated RNase A.
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with 1% NP40). In addition, the ALPs encapsulated the siRNA to an ex-
tremely high level, these results indicate that ALPs may have inside
and outside asymmetric distributions of lipids, siRNA, and buffer
solutions.
3.2. Stability and toxicity of siRNA/ALPs
Free siRNA degrades rapidly on account of nucleases in the blood-
stream and body ﬂuids. It is therefore important to protect siRNA
from nucleases. Potent RNase A was used to investigate the stability
of the siRNA encapsulated in ALPs. Although RNase A completely de-
grades the free siRNA within 1 h, the siRNA encapsulated in ALPs was
protected from enzyme degradation for up to 24 h (Fig. 3A). ALPs also
protect siRNA from 50% mouse sera (Fig. 3B), which means the lipid
bilayers of ALPs protect the nuclease access to the encapsulated
siRNA.
The cationic lipids in liposomes induce aggregation through elec-
trostatic interaction between liposomes and the negatively charged
species in serum, and the aggregation prevents liposome circulation
in blood [31]. No aggregation was found in the mixture of siRNA/
ALPs and serum (Supplementary Fig. 2), which means the negatively
charged and PEGylated surface of ALPs prevents the aggregation.Fig. 4. Cellular uptake of ALPs with and without R12 modiﬁcation. The four cell lines NIH-3
without R12 modiﬁcation on their outer layers. The non-conjugated ALPs (NC) show no pen
efﬁciency in all the cell lines because R12 induces a nonspeciﬁc cellular uptake.In general the cationic liposomes display the toxicity at the high
lipid concentration. However, the siRNA/ALPs showed almost no tox-
icity even at the 6.4 μmol/ml lipid concentration prepared by mixing
80 μl cell culture medium and 20 μl ALP solution in HBS. The viability
for NSCLC cells and NIH-3T3 cells was 97–100% and 90% after 24 h in-
cubation, respectively (data not shown).
3.3. Polyarginine-mediated uptake of siRNA/ALPs
FITC-siRNA was used to monitor the cellular uptake of the siRNA
encapsulated in ALPs. More than 90% of the FITC-siRNA was also en-
capsulated in ALPs (data not shown). The liposomes with a positively
charged surface cannot totally prevent the liposome uptake, even
with PEGylated lipids [32]. The miPEG-PE on the surface of the ALPs
was introduced to conjugate ligands with the sulfhydryl groups. The
siRNA encapsulation, particle size, and zeta potential of the FITC-
siRNA/ALPs with miPEG-PE are compatible to those of the ALPs
shown in Fig. 2. The ALPs with negatively charged surface showed
no uptake into cells without surface modiﬁcation (Fig. 4). It has
been reported that polyarginine effectively delivers liposome into
cells and induces siRNA-mediated gene-silencing [33]. In this study,
the R12-modiﬁed FITC-siRNA/ALPs were prepared by conjugation be-
tween the sulfhydryl group of R12 and the maleimide group of
miPEG-PE on the ALPs. The R12-modiﬁed ALPs are effectively inter-
nalized into all the cells in the presence of 10% FBS (Fig. 4). The inter-
nalized FITC-siRNA is predominantly located at the endosome (Fig. 4),
which means the R12-modiﬁed FITC-siRNA may be internalized by
the endocytotic process as reported previously [34,35]. This pattern
is similar to the pattern of LF2K-mediated FITC-siRNA transfection
(data not shown).
3.4. Antibody-mediated cell-speciﬁc uptake of siRNA/ALPs
The NSCLC cell lines have been reported to overexpress EGFR [36].
The anti-EGFR antibody Erbitux induces internalization of the anti-
body in cervical cancer cells [37]. A recent report indicates that the
anti-EGFR antibody can be used to deliver siRNA/liposomes to breast
cancer cells that overexpress EGFR [32]. In this study, we initially test-
ed the EGFR expression on the surface of the NSCLC cells (A549, NCI-
H322, and NCI-H322) and the NIH-3T3 cells. As expected, the anti-
body effectively interacts with all the NSCLC cell lines but not with
the NIH-3T3 cells (data not shown). The FITC-modiﬁed antibody is in-
ternalized into the NSCLC cells by mean of the EGFR-mediated endo-
cytosis but not into the NIH-3T3 cells, and predominantly localize at
the cytoplasm after overnight incubation (Supplementary Fig. 3).T3, A 549, NCI-H322, and NCI-H 460 were transfected with FITC-siRNA/APLs with and
etration into any of the cell lines, whereas the R12-modiﬁed ALPs display a high uptake
Fig. 5. Cellular uptake of ALPs modiﬁed with a thiolated antibody and Fab′. The four cell lines NIH-3T3, A 549, NCI-H322, and NCI-H 460 were transfected with FITC-siRNA/APLs
modiﬁed with a thiolated anti-EGFR (tAb) or Fab′ (tFab′) on their outer layers. All the modiﬁed ALPs display a high uptake efﬁciency in the NSCLC cell lines due to the human
EGFR expression on their surface but not in the NIH-3T3 cells in which there is no human EGFR expression.
Fig. 6. In vitro luciferase gene-silencing by siGL3. NCI-H322 cells ﬁrst were transfected
by pGL3 — control vector were treated with either siGL3 or scrambed siRNA (siSC) in a
complex with lipofectamine 2000 (LF2K) or encapsulated in ALPs with or without tAb
conjugation (NC or tAb, respectively). The luciferase activities were measured 48 h
after the transfection of siRNA. NT refers to no siRNA treatement.
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tried to conjugate the Fab′ with the free thiol group to the maleimide
groups on the ALPs. Unfortunately, the conjugation of the Fab′ to the
ALPs failed (data not shown), even though we incubated the mixture
of Fab′ and ALPs overnight at room temperature. We consequently
used 2-imminothiolane to thiolate the anti-EGFR antibody and Fab′
[32], and named tAb and tFab′, respectively. Four to ﬁve free thiol
groups per a molecule of antibody or Fab′ were formed after the 2-
imminothiolane treatment. Then tAb was incubated with biotin mal-
eimide (Sigma, USA) to test whether the thiolation changes the anti-
body property. The results show that the biotinylated tAb was
effectively internalized into the NSCLC cells but not into the NIH-
3T3 cells (Supplementary Fig. 3), which suggests that the thiolation
does not change the antibody-mediated endocytosis. Finally tAb or
tFab′ was conjugated to the FITC-siRNA/ALPs. Because the antibody
is hard to remove by dialysis, we used buoyant density gradient cen-
trifugation with sucrose gradients to remove any unattached anti-
body or Fab′. Most of the unattached antibody was found at the
bottom fraction (37% sucrose), but no siRNA appeared in the bottom
fraction (data not shown). The ALPs were localized in the 9% sucrose
regardless of the conjugating molecules. The puriﬁed ALPs possess
the encapsulated siRNA as well as the antibody that is attached to
the miPEG-PE (Supplementary Fig. 4A and 4B, respectively). In addi-
tion, the density gradient method was found to be useful for eliminat-
ing the non-encapsulated siRNA. The tAb-modiﬁed and tFab′-
modiﬁed FITC-siRNA/ALPs were internalized into all three NSCLC
cells but not into the NIH-3T3 cells (Fig. 5).
3.5. Gene-silencing of siRNA/ALPs
Because siRNA induces gene-silencing in cytoplasm, the intracel-
lular siRNA delivery does not reﬂect its function in cells. In this
study, we used siGL3 and siTMPR4 as model systems to investigate
the gene-silencing function of siRNA/ALPs in cells. Unmodiﬁed
siGL3/ALPs show almost no ability to prevent luciferase activity,
whereas tAb-modiﬁed ALPs elicit a similar level of inhibition with
LF2K (Fig. 6). However, particles with scrambled siRNA fail to prevent
luciferase activity.
TMPRSS4 is upregulated in many cancer cells and induces many
oncogenic functions, including tumor cell adhesion, migration, inva-
sion and in vitro growth. These functions can be reversed with a
TMPRSS4 knockdown induced by siTMPR4 [30]. The results of our
analysis, which involved in TMPRSS4 mRNA depletion with both
commercially available transfecting reagents LF2K and siTMPR4/
25 K polyethyleneimine, conﬁrm the gene-silencing effect of siTMPR4(Fig. 7A and B, respectively). In addition, compared with a previous
report on scrambled siRNA [30], the TMPRSS4 knockdown signiﬁcant-
ly suppresses NCI-H322 cell invasion and NCI-H322 cell migration
(Fig. 7A and B, respectively).
As shown in Fig. 7C and D, the unmodiﬁed siTMPR4/ALPs (NC),
which cannot penetrate the cells, show no ability to prevent TMPRSS4
transcription and any cell migration and invasion. However, the R12-
modiﬁed siTMPR4/ALPs signiﬁcantly inhibit the TMPRSS4 transcrip-
tion as well as the cell migration and invasion (Fig. 7C). The results
indicate that the internalized siTMPR4/ALPs effectively induce siRNA-
dependent TMPRSS4 gene-silencing.
The tAb-modiﬁed and tFab′-modiﬁed siTMPR4/ALPs signiﬁcantly
inhibit the TMPRSS4 transcription as compared with the unmodiﬁed
siTMPR4/ALPs (Fig. 7D). Interestingly, the TMPRSS4 knockdown was
also induced by treatment with tAb-modiﬁed and tFab′-modiﬁed
scrambled siRNA/ALPs. The TMPRSS4 depletion was synergistically
enhanced by the siTMPR4. The synergistic effects of siTMPR4 and
the anti-hEGFR antibody (tAb) or Fab′ (tFab) also observed in the
study of the cell migration and invasion in correlation with the
TMPRSS4 knockdown (Fig. 7D). The anti-EGFR antibody (Erbitux)
evokes tumoricidal activity in cancer cells expressing EGFR.We there-
fore assume that the inhibition of the EGFR function by the antibody
may also inhibit the TMPRSS4 expression, though further study of
this assumption is needed.
Fig. 7. TMPRSS4 knockdown and inhibitions of cell migration and invasion by siTMPR4. NCI-H322 cells were treated with siTMPR4 and siSC under various conditions. After 48 h of
incubation, the cells were harvested and subjected to total RNA extraction and invasion as well as cell migration assays. The TMPRSS4 mRNA levels were determined by RT-PCR, and
β-Actin was used as an internal control. For invasion and migration assays, 4×104 cells were allowed to migrate or invade Matrigel for 48 h. Representative high-power (×200)
ﬁelds (HPFs) were photographed, and the number of cells that had migrated or invaded was counted in six to eight representative HPFs per Transwell insert. The siSC complex
with LF2K or PEI25K and the siTMPR4/ALPs without conjugation (NC) were used as controls. The values are the mean plus or minus the standard deviation (*Pb0.05 and
**Pb0.01). The samples of siSC and siTMPR4 were transfected by using (A) LF2K, (B) PEI25K, (C) ALPs conjugated with R12, and (D) ALPs conjugated with tAb or tFab′.
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Our aim in this study is to develop a novel method of producing
ALPs that satisfy two goals: a higher siRNA encapsulation efﬁciency
and a negatively charged surface that provides less nonspeciﬁc ab-
sorption [38,39]. Lipids with small head groups can stabilize an
inverted micelle structure, whereas lipids with large head groups de-
stabilize an inverted micelle structure. We assume that an unstable
outer inverted micelle has the potential to quickly disrupt and sur-
round the outside of the inner inverted micelle during organic solvent
evaporation as shown in Fig. 1.
We initially focused on DODAP. Depending on the pH level,
DODAP can participate in a strong interaction with siRNA. The
siRNA encapsulation was successful when we used a combination ofDODAP and DOPE (9:1) at pH 4.0 to make the inner inverted micelle.
Unexpectedly, the increase of pH to 5.0 induced almost no siRNA en-
capsulation (Fig. 2A), and the complete removal of the inner DOPE
prevents the formation of the inner inverted micelle structure (data
not shown). A possible explanation for this behavior is that the
dimethylammonium group of DODAP can be more strongly hydroge-
nated at pH 4.0 than pH 5.0 and the interaction between the hydro-
gen atom of DODAP and the oxygen atom(s) of the phosphate
group of DOPE (Supplementary Fig. 5) may have stabilized the inner
compartment of ALPs. In this aspect, DOTAP without ionizable hydro-
gen cannot form the hydrogen interaction with DOPE, and this and its
large head group may make the unstable inner compartment. We as-
sume that the property of DOTAP may induce almost no encapsula-
tion of siRNA (Fig. 2A). The outer lipids are less critical than the
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the particle size and encapsulation (Fig. 2B).
We subsequently studied the ALP delivery in cells. The fact that
there is no cellular delivery of the ALPs without any surface modiﬁca-
tion, as shown in Fig. 4, is not surprising because the particles have a
negatively charged and PEGylated surface. In other words, the ALPs
without any nonspeciﬁc delivery have great potential for being devel-
oped as cargo for the target-speciﬁc delivery of siRNA after being con-
jugated with a target-speciﬁc ligand. Indeed, the conjugation of the
ligands (R12 and anti-EGFR antibody) to ALPs remarkably enhances
the cellular uptake of ALPs (Figs. 4 and 5). Moreover, the anti-EGFR
conjugation induces the target cell-speciﬁc delivery (Fig. 5).
The direct conjugation of the Fab′ sulfhydryl group to the malei-
mide groups on ALPs was not successful (data not shown). One possi-
ble explanation is that the cysteine sulfhydryl group in Fab′ may be
insufﬁcient to access the maleimide group on huge ALPs. In contrast,
as previously reported [32], when 2-imminothiolane is used for the
thiolation at the lysine residues of the antibody, there is enough
space for the ALPs. SDS-PAGE was used to demonstrate the multiple
conjugations of miPEG-PE to tAb and tFab′ (Supplementary Fig. 4),
and the multiple conjugations indicate the need to control the attach-
ment of the thiolated antibody. Although nonspeciﬁc thiolation hin-
ders the uniform conjugation of the antibody or Fab′ to the ALPs, the
conjugation can induce an antibody-speciﬁc ALP uptake (Fig. 5).
An endosomal escape of siRNA is required for the siRNA action be-
cause the target gene-silencing takes place in a cytoplasm. Although we
primarily observed the siRNA in the endosome compartment (Figs. 4
and 5), the ALP uptake capability was clearly depending on the gene-
silencing efﬁciency (Figs. 6 and 7). One possible explanation is the time
and siRNA differences in the experiments. For a delivery assay, the cells
were monitored 24 h after being treated with FITC-siRNA. And for a
gene-silencing assay, the cells were collected 48 h after being treated
with siRNA in the absence of any ﬂuorescence dye. In addition, we
found similar distribution in the FITC-siRNA transfected by LF2K
which is generally used for siRNA-mediated gene-silencing (data not
shown), supporting our explanation. We assume that the endosomal
escape of FITC-siRNA is slower than that of non-labeled siRNA.
The anti-EGFR antibody Erbitux evokes anticancer activity for
EGFR-bearing cells by inhibiting EGFR autophosphorylation [40]. It
considered as an effective treatment for NSCLC as a supplement to
platinum-based chemotherapy [41]. According to this view, the anti-
body and Fab′-mediated anticancer activity may be related to signiﬁ-
cant reduction of the TMPRSS4 transcription as well as the inhibition
of the cell migration and invasion regardless of the siRNA content. Be-
cause the antibody did not inhibit the β-actin transcription (Fig. 7D),
the TMPRSS4 knockdown can possibly be explained in terms of the
association with its anti-EGFR function, such as the inhibition of
EGFR autophosphorylation. The fact that the antibody does not inhibit
the luciferase expression supports this assumption (Fig. 6). The
TMPRSS4 knockdown is synergistically enhanced by the siTMPR4
(Fig. 7D). The co-treatment of the anti-EGFR antibody and siTMPR4
may be useful for cancer therapy of those cells that express both pro-
teins, and the ALPs can be used as cargo for the antibody and siRNA.
In conclusion, we developed a method of preparing ALPs with a
high siRNA encapsulation efﬁciency as well as a negatively charged
surface that prevents nonspeciﬁc uptake of the ALPs. The ALP internal-
ization can be induced by conjugation of R12 or the EGFR antibody,
and the siRNA in the internalized ALPs can successfully induce
siRNA-dependent gene-silencing activity. Taken together, these re-
sults demonstrate that ALPs may be useful cargo for the delivery of
target-speciﬁc siRNA.
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